Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212852 | 0.84 | LMNA (0.50) | LMNAMAPTMEN1KMT2ATP53 | |
| SCHEMBL24027843 | 0.84 | LMNA (0.50) | LMNAMAPTMEN1KMT2ATP53 | |
| SCHEMBL24027840 | 0.83 | RXFP1 (0.54) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL30255954 | 0.83 | RXFP1 (0.54) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL24027846 | 0.80 | IDH2 (0.43) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL30255658 | 0.80 | LMNA (0.46) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL24027845 | 0.80 | LMNA (0.46) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL17925886 | 0.79 | MEN1 (0.57) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL2096025 | 0.78 | MAPT (0.75) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL30130682 | 0.78 | MAPT (0.75) | LMNAMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | LMNA 4314/4885MAPT 2167/4885MEN1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.